SCHEMBL3449140

SCHEMBL3449140

Cc1ncc2n1C(=O)N(N1CCN(C(=O)C(NC(=O)Nc3ccc(Cl)cc3)c3cccs3)CC1)C2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 3/20 0.44
RAB9A P51151 5/20 0.41
NPC1 O15118 3/20 0.41
HTT P42858 3/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 5/20 0.36
TP53 P04637 1/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
NR3C1 P04150 1/20 0.35
F2 P00734 1/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
POLB P06746 1/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
ALDH1A1 P00352 2/20 0.34
CCR1 P32246 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3449335 0.87 F10 (0.46) F10RAB9ALMNAMAPTSMN1; SMN2
SCHEMBL3449849 0.87 F10 (0.46) F10RAB9ALMNAMAPTSMN1; SMN2
SCHEMBL3448452 0.87 F10 (0.42) F10LMNAL3MBTL1F2MEN1
SCHEMBL3450747 0.86 F10 (0.49) F10RAB9ANPC1HTTLMNA
SCHEMBL3451344 0.83 CCR1 (0.48) F10F2CCR1
SCHEMBL3451874 0.82 F10 (0.47) F10RAB9AMAPTSMN1; SMN2NR3C1
SCHEMBL3450303 0.82 F10 (0.47) F10RAB9AMAPTSMN1; SMN2NR3C1
SCHEMBL3449908 0.82 F10 (0.47) F10RAB9AMAPTSMN1; SMN2NR3C1
SCHEMBL3452169 0.82 F10 (0.46) F10RAB9AMAPTSMN1; SMN2NR3C1
SCHEMBL3449086 0.81 F10 (0.46) F10RAB9ANPC1SMN1; SMN2NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820673-B2 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-26 US disclosed
US-7820673-B2 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-26 US disclosed
US-7820673-B2 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-26 US disclosed
US-20070093501-A1 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-04-26 US disclosed
US-20070093501-A1 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-04-26 US disclosed
US-20070093501-A1 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-04-26 US disclosed
EP-1695961-A1 UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2006-08-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093501-A1 Urea derivative, process for producing the same, and use F2, URB2, F12 F10 22/4885RAB9A 3460/4885NPC1 3304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.